What is partial response vs complete response in Triple-Negative Breast Cancer treatment

Understanding Partial vs. Complete Response in Triple-Negative Breast Cancer

I'll explain what these response types mean and why they matter for your treatment decisions.

Complete Response (CR)

A complete response means that after treatment, imaging scans (like CT or PET scans) show no detectable cancer. The tumor has either disappeared entirely or shrunk below the level that can be measured on imaging.

Important context: Even with a complete response, microscopic cancer cells may still exist that imaging cannot detect. This is why ongoing monitoring remains important.

Partial Response (PR)

A partial response means the tumor has shrunk by at least 30% in size, but some cancer remains visible on imaging. The cancer hasn't disappeared, but the treatment is working to reduce it.

Clinical significance: According to the webinar on functional precision testing, partial responses carry important implications for treatment durability. As one expert explained, if a drug shows only a partial response (like 50% of cancer cells responding), there's a significantly higher chance you'll develop resistance much sooner compared to a drug producing a complete response where 100% of cells respond.

Why This Distinction Matters for TNBC

Triple-negative breast cancer is particularly aggressive because it lacks three common treatment targets (ER, PR, and HER2 receptors), making it harder to treat with hormone or targeted therapies. This means:

• Complete responses are more valuable because they suggest the treatment is effectively eliminating cancer cells across the board
• Partial responses may require closer monitoring and potentially earlier consideration of switching treatments before resistance develops

Questions to Ask Your Oncologist

1. What type of response are we seeing with my current treatment? (Complete, partial, or stable disease?)
2. If I have a partial response, what's the plan for monitoring resistance development?
3. How often will we reassess my response, and what triggers a treatment change?
4. Are there biomarkers we can track (like circulating tumor DNA) between imaging scans to catch resistance early?
5. If resistance develops, what are the next treatment options we've already identified?

Monitoring Strategy

According to molecular integrative oncology approaches, oncologists typically evaluate response at 3-month intervals with imaging or other assessments, then make decisions about continuing, modifying, or changing treatment based on those results. This structured approach helps catch resistance patterns before they become problematic.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.